Julie Anne Smith has joined E-Scape Bio as president and CEO of the San Francisco company. She has also joined the neurological drug developer’s board of directors. Before coming E-Scape, Smith was president and CEO of Menlo Park, CA-based Nuredis. Smith’s experience also includes executive posts at Raptor Pharmaceuticals and Enobia Pharmaceuticals. Last year, E-Scape raised $63 million in a Series A round of investment. The company’s lead program, an experimental treatment for central nervous system-related lysosomal storage disorders, is expected to enter clinical trials in 2019.
